GSK Bio

Rheostat Therapeutics today announced the close of a Series A financing round totaling $23 million.

Exscientia, the company leading the use of Artificial Intelligence (AI) in drug discovery, announces that is has acquired the biophysics specialists, Kinetic Discovery, a private UK company. The acquisition builds up Exscientia’s capabilities for tackling novel drug targets to create first-in-class drug candidates by seeding its algorithms with data generated through the use of fragment screening and structural biology.

Sareum Holdings plc is pleased to announce the appointments of Michael Owen, PhD and Clive Birch as Non-Executive Directors.

Consilium Strategic Communications today announces the appointment of Alex Harrison as a Senior Advisor.

YUPELRI (revefenacin) is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US

The number of life science jobs grew by 12,500 for an approximate total of a total estimated employment of 311,226. That was music to the ears of Sara Radcliffe, president and chief executive officer of the California Life Sciences Association.

This deal is an expansion of an existing discovery collaboration. Immunocore will head the first-in-human clinical trial of the drug alone and in combination with Genentech’s checkpoint inhibitor Tecentriq (atezolizumab).

Kiadis Pharma N.V. today announces that it has appointed three new senior team members to further strengthen the Company as it transitions into commercial stage.

The UK’s exit from the European Union, Brexit, will impact numerous industries in the UK and Europe, but the biopharma industry has its own unique challenges.